Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia
暂无分享,去创建一个
Philippe Dessen | Olivier Hermine | Nicolas Boissel | Vahid Asnafi | Elizabeth Macintyre | Isabelle Radford-Weiss | S. Agarwal | H. Dombret | E. Macintyre | P. Dessen | C. Beaumont | I. Moura | M. Benhamou | R. Monteiro | I. Radford‐Weiss | O. Hermine | V. Asnafi | N. Boissel | E. Raffoux | J. Ribeil | Emmanuel Raffoux | Hervé Dombret | M. Rubio | Carole Beaumont | C. Callens | Marc Benhamou | Ivan C. Moura | Renato C. Monteiro | Celine Callens | Séverine Coulon | Jerome Naudin | Pamella Huey Mei Wang | Saurabh Agarwal | Houda Tamouza | Etienne Paubelle | Jean-Antoine Ribeil | Danielle Canioni | Olivia Chandesris | Marie Therese Rubio | D. Canioni | E. Paubelle | O. Chandesris | J. Naudin | S. Coulon | Houda Tamouza | P. Wang
[1] C. Felix,et al. The molecular basis of leukemia. , 2004, Hematology. American Society of Hematology. Education Program.
[2] D. Gilliland,et al. Genetics of myeloid leukemias. , 2003, Annual review of genomics and human genetics.
[3] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[4] P. Pandolfi,et al. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation , 2008, Nature Medicine.
[5] H. Kantarjian,et al. Progress in the treatment of acute myeloid leukemia , 2007, Cancer.
[6] Tina N. Davis,et al. Proteomic and genetic approaches identify Syk as an AML target. , 2009, Cancer cell.
[7] H. Mcardle,et al. Transferrin-receptor interaction and iron uptake by reticulocytes of vertebrate animals — a comparative study , 2004, Journal of Comparative Physiology B.
[8] A. Friedman. Transcriptional regulation of granulocyte and monocyte development , 2002, Oncogene.
[9] W. Faulk,et al. TRANSFERRIN AND TRANSFERRIN RECEPTORS IN CARCINOMA OF THE BREAST , 1980, The Lancet.
[10] B. Verhasselt,et al. HOX-A10 regulates hematopoietic lineage commitment: evidence for a monocyte-specific transcription factor. , 2002, Blood.
[11] N. Brousse,et al. Prevention of mantle lymphoma tumor establishment by routing transferrin receptor toward lysosomal compartments. , 2007, Cancer research.
[12] S. Armstrong,et al. FoxOs Are Critical Mediators of Hematopoietic Stem Cell Resistance to Physiologic Oxidative Stress , 2007, Cell.
[13] H. DeLuca,et al. Induction of macrophage differentiation of human normal and leukemic myeloid stem cells by 1,25-dihydroxyvitamin D3 and its fluorinated analogues. , 1984, Cancer research.
[14] Claudia A. Garay-Canales,et al. 1α, 25‐Dihydroxy‐vitamin D3 alters syk activation through FcγRII in monocytic THP‐1 cells , 2003 .
[15] Xuening Wang,et al. Jun N‐terminal kinase pathway enhances signaling of monocytic differentiation of human leukemia cells induced by 1,25‐dihydroxyvitamin D3 , 2003, Journal of cellular biochemistry.
[16] D. Richardson,et al. Iron trafficking in the mitochondrion: novel pathways revealed by disease. , 2005, Blood.
[17] J. Ito,et al. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation , 2008, Bone Marrow Transplantation.
[18] A. Whitmarsh,et al. Signal Transduction by MAP Kinases: Regulation by Phosphorylation-Dependent Switches , 1999, Science's STKE.
[19] M. Minden,et al. Heterozygous PU.1 mutations are associated with acute myeloid leukemia. , 2002, Blood.
[20] V. Pullarkat. Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye? , 2009, Blood.
[21] J. Ambrus,et al. Effect of 1,25(OH)2 Vitamin D3 Analogs on Differentiation Induction and Cytokine Modulation in Blasts from Acute Myeloid Leukemia Patients , 2004, Leukemia & lymphoma.
[22] J. Larghero,et al. 1 alpha,25-dihydroxyvitamin D3 transrepresses retinoic acid transcriptional activity via vitamin D receptor in myeloid cells. , 2004, Molecular endocrinology.
[23] R. Salgia,et al. Hematopoietic growth factors signal through the formation of reactive oxygen species. , 1999, Blood.
[24] U. Banerjee,et al. Reactive Oxygen Species prime Drosophila haematopoietic progenitors for differentiation , 2009, Nature.
[25] L. Zimmerman,et al. THE COMBINED USE OF MICROINCINERATION AND THE PRUSSIAN BLUE REACTION FOR A MORE SENSITIVE HISTOCHEMICAL DEMONSTRATION OF IRON , 1964, Journal of Histochemistry and Cytochemistry.
[26] C. Proud,et al. Methods for studying signal-dependent regulation of translation factor activity. , 2007, Methods in enzymology.
[27] David A. Hume,et al. The JNK Are Important for Development and Survival of Macrophages , 2006, The Journal of Immunology.
[28] H. Gralnick,et al. Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group , 1976, British journal of haematology.
[29] G. P. Studzinski,et al. Retinoblastoma Protein and CCAAT/Enhancer-Binding Protein β Are Required for 1,25-Dihydroxyvitamin D3-Induced Monocytic Differentiation of HL60 Cells , 2004, Cancer Research.
[30] D. Trump,et al. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics , 2007, Nature Reviews Cancer.
[31] T. Chou,et al. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.
[32] Ewa Marcinkowska,et al. Vitamin D3-driven signals for myeloid cell differentiation--implications for differentiation therapy. , 2010, Leukemia research.
[33] N. Holbrook,et al. Cellular response to oxidative stress: Signaling for suicide and survival * , 2002, Journal of cellular physiology.
[34] D. Richardson,et al. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell. , 1994, Cancer research.
[35] D. Richardson,et al. Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion. , 2007, Blood.
[36] H. Döhner,et al. High-dose daunorubicin in older patients with acute myeloid leukemia. , 2009, The New England journal of medicine.
[37] A. Renand,et al. Recent advances in adult T-cell leukemia therapy: focus on a new anti-transferrin receptor monoclonal antibody , 2008, Leukemia.
[38] D. Richardson,et al. Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. , 2009, Biochimica et biophysica acta.
[39] C. Preudhomme,et al. Cooperation of activating Ras/rtk signal transduction pathway mutations and inactivating myeloid differentiation gene mutations in M0 AML: a study of 45 patients , 2006, Leukemia.
[40] T. Daniels,et al. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. , 2006, Clinical immunology.
[41] W. Breuer,et al. A review of fluorescence methods for assessing labile iron in cells and biological fluids. , 2002, Analytical biochemistry.
[42] G. Kansas,et al. Expression of the CD11/CD18, leukocyte adhesion molecule 1, and CD44 adhesion molecules during normal myeloid and erythroid differentiation in humans. , 1990, Blood.
[43] J. O'kelly,et al. Vitamin D(2) analog (Paricalcitol; Zemplar) for treatment of myelodysplastic syndrome. , 2005, Leukemia research.
[44] Zhen-yi Wang,et al. Acute promyelocytic leukemia: from highly fatal to highly curable. , 2008, Blood.
[45] I. Trowbridge,et al. Structure and function of transferrin receptors and their relationship to cell growth. , 1986, Biochemical Society symposium.
[46] D. Mason,et al. Transferrin receptors in human tissues: their distribution and possible clinical relevance. , 1983, Journal of clinical pathology.
[47] M. Herlyn,et al. Rewired ERK-JNK signaling pathways in melanoma. , 2007, Cancer cell.
[48] M. Davies,et al. The oxidative environment and protein damage. , 2005, Biochimica et biophysica acta.
[49] M. Cooper,et al. Identification of the Transferrin Receptor as a Novel Immunoglobulin (Ig)a1 Receptor and Its Enhanced Expression on Mesangial Cells in Iga Nephropathy , 2001, The Journal of experimental medicine.
[50] L. Galluzzi,et al. Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparison. , 2008, Biochemical pharmacology.
[51] C. Preudhomme,et al. Cooperating gene mutations in acute myeloid leukemia: a review of the literature , 2008, Leukemia.
[52] V. Lallemand-Breitenbach,et al. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARα catabolism, role of oncogene degradation in disease remission , 2001, Oncogene.
[53] D. Richardson,et al. Potent Antitumor Activity of Novel Iron Chelators Derived from Di-2-Pyridylketone Isonicotinoyl Hydrazone Involves Fenton-Derived Free Radical Generation , 2004, Clinical Cancer Research.
[54] I. Moura,et al. A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients , 2004, Retrovirology.
[55] A. Friedman. Transcriptional control of granulocyte and monocyte development , 2007, Oncogene.
[56] S. Fröhling,et al. Genetics of myeloid malignancies: pathogenetic and clinical implications. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] Trowbridge Is,et al. Structure and function of transferrin receptors and their relationship to cell growth. , 1986 .
[58] G. Johnson,et al. Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases , 2002, Science.
[59] M. Haussler,et al. Human vitamin D receptor phosphorylation by casein kinase II at Ser-208 potentiates transcriptional activation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[60] I. Trowbridge,et al. Anti-transferrin receptor monoclonal antibody and toxin–antibody conjugates affect growth of human tumour cells , 1981, Nature.
[61] J. Adamson,et al. The relationship of erythropoietin and iron metabolism to red blood cell production in humans. , 1994, Seminars in oncology.
[62] Z. Wang,et al. Retinoic acid and acute promyelocytic leukemia: a model of targetting treatment for human cancer. , 1994, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.
[63] D. Richardson,et al. Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. , 2004, Blood.
[64] D. Richardson,et al. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics , 2006, Proceedings of the National Academy of Sciences.
[65] M. Konopleva,et al. Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia , 2005, Leukemia.
[66] N. Reiner,et al. 1α,25-Dihydroxyvitamin D3–Induced Myeloid Cell Differentiation Is Regulated by a Vitamin D Receptor–Phosphatidylinositol 3-Kinase Signaling Complex , 1999, The Journal of experimental medicine.
[67] T. Graf,et al. MafB Is an Interaction Partner and Repressor of Ets-1 That Inhibits Erythroid Differentiation , 1996, Cell.
[68] B. Kalyanaraman. Iron signaling and oxidant damage , 2007, Cardiovascular Toxicology.
[69] M. Boccadoro,et al. Differentiating agents + low-dose chemotherapy in the management of old/poor prognosis patients with acute myeloid leukemia or myelodysplastic syndrome. , 2004, Haematologica.
[70] Utpal Banerjee,et al. Distinct mitochondrial retrograde signals control the G1-S cell cycle checkpoint , 2008, Nature Genetics.
[71] Gustavo Helguera,et al. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. , 2006, Clinical immunology.
[72] Francesco Ferrari,et al. The Vitamin D3/Hox-A10 Pathway Supports MafB Function during the Monocyte Differentiation of Human CD34+ Hemopoietic Progenitors1 , 2008, The Journal of Immunology.
[73] T. Graf,et al. A transcription factor party during blood cell differentiation. , 1998, Current opinion in genetics & development.
[74] H. Sakagami,et al. Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[75] M. Benhamou,et al. Phospholipid Scramblase 1 Modulates a Selected Set of IgE Receptor-mediated Mast Cell Responses through LAT-dependent Pathway* , 2008, Journal of Biological Chemistry.